EPS for Gilead Sciences, Inc. (GILD) Expected At $1.67; Miragen Therapeutics (MGEN) Shorts Lowered By 15.55%

January 27, 2018 - By Darrin Black

Analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to report $1.67 EPS on February, 6.They anticipate $0.97 EPS change or 36.74% from last quarter’s $2.64 EPS. GILD’s profit would be $2.18 billion giving it 12.79 P/E if the $1.67 EPS is correct. After having $2.23 EPS previously, Gilead Sciences, Inc.’s analysts see -25.11% EPS growth. The stock increased 5.26% or $4.27 during the last trading session, reaching $85.46. About 14.62 million shares traded or 79.43% up from the average. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 27, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Miragen Therapeutics Incorporated (NASDAQ:MGEN) had a decrease of 15.55% in short interest. MGEN’s SI was 344,900 shares in January as released by FINRA. Its down 15.55% from 408,400 shares previously. With 67,300 avg volume, 5 days are for Miragen Therapeutics Incorporated (NASDAQ:MGEN)’s short sellers to cover MGEN’s short positions. The SI to Miragen Therapeutics Incorporated’s float is 62.29%. The stock increased 0.59% or $0.05 during the last trading session, reaching $8.58. About 73,052 shares traded. Miragen Therapeutics, Inc. (NASDAQ:MGEN) has 0.00% since January 27, 2017 and is . It has underperformed by 16.70% the S&P500.

Since August 1, 2017, it had 0 buys, and 13 sales for $51.52 million activity. Washington Robin L sold 51,820 shares worth $4.40M. $2.07 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Alton Gregg H. $5.56M worth of stock was sold by MARTIN JOHN C on Tuesday, August 1. Meyers James R sold $8.02M worth of stock or 100,000 shares.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 20 have Buy rating, 0 Sell and 10 Hold. Therefore 67% are positive. Gilead Sciences had 113 analyst reports since July 29, 2015 according to SRatingsIntel. As per Friday, December 18, the company rating was initiated by Atlantic Securities. As per Wednesday, March 23, the company rating was maintained by Credit Suisse. On Wednesday, October 4 the stock rating was maintained by Bank of America with “Neutral”. The firm has “Outperform” rating by BMO Capital Markets given on Friday, October 27. The firm has “Buy” rating given on Tuesday, September 6 by Jefferies. The firm has “Outperform” rating given on Monday, October 3 by RBC Capital Markets. Citigroup maintained it with “Buy” rating and $105 target in Friday, April 29 report. The rating was initiated by Stifel Nicolaus on Monday, November 14 with “Buy”. Oppenheimer initiated it with “Outperform” rating and $120 target in Thursday, February 11 report. The rating was downgraded by Argus Research on Friday, July 29 to “Hold”.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Moreover, Homrich Berg has 0.05% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 7,577 shares. Washington Trust Company holds 4,401 shares or 0.02% of its portfolio. Renaissance Group Llc, Massachusetts-based fund reported 2,530 shares. Whittier Trust Of Nevada has 0.77% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 102,715 shares. Moreover, Jane Street Group Inc Inc Limited Liability Corporation has 0.12% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Retirement Of Alabama reported 0.44% in Gilead Sciences, Inc. (NASDAQ:GILD). New York-based Gideon Capital Advisors Inc has invested 0.46% in Gilead Sciences, Inc. (NASDAQ:GILD). Swiss Bancorp stated it has 4.82 million shares. Hollencrest Securities Limited Liability reported 0.1% in Gilead Sciences, Inc. (NASDAQ:GILD). Los Angeles Cap & Equity Rech invested 0.15% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Bogle Investment Management Lp De holds 0.72% or 131,376 shares. Main Street Ltd Liability Corp reported 0.08% stake. Winslow Evans And Crocker reported 31,412 shares stake. Johnson Group Incorporated owns 0.4% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 37,861 shares. Natixis Asset Mngmt holds 95,651 shares or 0.67% of its portfolio.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $111.63 billion. The companyÂ’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 9.73 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $191.42 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.